Author Archive for: TG

At BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions.

BioSpain 2025 opened in Barcelona, the capital of Catalonia, setting a new record for both visitors and exhibitors. During the inauguration, representatives from government and industry highlighted the leading role of biotechnology in building economic and environmental resilience in Spain and across the European Union.

Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?

The U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.

Rezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.